国立がん研究センターがViewRayのMRIdianシステムで初の患者治療
国立がん研究センターがViewRayのMRIdianシステムで初の患者治療
AsiaNet 69076 (0947)
【クリーブランド2017年6月27日PR Newswire=共同通信JBN】
*肺、肝臓、すい臓のがん患者にMRIガイド放射線治療の利点をもたらす
ViewRay, Inc.(ビューレイ社)(Nasdaq: VRAY)は27日、日本の国立がん研究センター(NCC、東京)が世界初で唯一の臨床MRIガイド放射線治療システムであるViewRayのMRIdian(メリディアン)システムを初めて患者治療に利用したと発表した。NCCで治療された初の適応症は肺、肝臓、すい臓のがんなどである。
MRIdianシステムはMRIのイメージングを放射線照射に組み合わせることで、いきいきと構造を捉え、すべてリアルタイムで臨床医は軟部組織を描出し、照射を調整することができる。MRIdianでは、他のイメージング方式では普通にある患者の余分な電離放射線被ばくを避けることができる。
NCC放射線治療科長の伊丹純医学博士は「MRIdianシステムで患者治療を始め、MRIと放射線照射の組み合わせの直接の利点と治療中に腫瘍と周辺の組織の動きや変化を把握する計画採用の価値がすでに認められることは喜ばしい。MRIdianにより、従来の放射線療法では治療不可能と考えられた一部患者を含め、治療するがん患者の数と種類を拡大できる」と語った。
日本国立がん研究センターは50年以上、患者のケアに携わってきた。NCCはがん治療研究の最先端にあり、がん医療に特化する医師、看護師、その他の医療専門家の育成で中心的役割を果たしている。
ViewRayのクリス・A・ラーネス社長兼最高経営責任者(CEO)は「NCCで日本初のMRIdianによる治療が行われていることに興奮している。MRIdianはリアルタイムの軟組織追跡と即時の適応照射の大きな長所がある。日本の患者ががん治療のこの重要な前進の恩恵を経験していることは喜ばしい」と述べた。
ViewRayは2016年8月に日本の厚生労働省からコバルト線源のMRIdianシステムの日本国内販売を承認された。ViewRayの日本での販売代理店は日本3大総合商社の1つ伊藤忠商事である。伊藤忠は約40年にわたり、日本の重要な医療イノベーションを促進するためヘルスケア事業を重視してきた。
▽ViewRayについて
ViewRay(R), Inc.(Nasdaq: VRAY)はMRIdian(R)放射線治療システムを設計、製造、販売している。MRIdianはMRI技術と放射線照射、照射中に軟組織腫瘍の位置と形状を特定、照準を合わせ、追跡する著作権のあるソフトウエアを一体化している。ViewRayはこの強化された視覚化と精度の組み合わせが患者治療の成果を大きく向上させると信じている。
ViewRayとMRIdianはViewRay, Inc.の登録商標である。
ソース:ViewRay, Inc.
▽問い合わせ先
Michael Saracen
Senior Director, Marketing, ViewRay, Inc.
Phone: +1-408-242-2994
Email: media@viewray.com
National Cancer Center Japan Treats First Patients Using ViewRay MRIdian System
PR69076
CLEVELAND, June 27, 2017 /PRNewswire=KYODO JBN/ --
- Brings Advantages of MRI-Guided Radiation Therapy to Treatment of Lung, Liver
and Pancreatic Cancer Patients
ViewRay, Inc. (Nasdaq: VRAY) announced today that the National Cancer Center
(NCC) in Tokyo, Japan treated its first patients using ViewRay's MRIdian
System, the world's first and only clinical MRI-guided radiation therapy
system. Among the first indications treated at NCC were cancers of the lung,
liver and pancreas.
The MRIdian System combines MR imaging with radiation delivery so clinicians
can visualize soft tissue and adjust their dosing - all in real-time, on live
anatomy. With MRIdian this is done without exposing the patient to the
additional ionizing radiation that is common with other imaging modalities.
"We're pleased to have commenced patient treatments with our MRIdian System and
are already seeing firsthand the benefits of combining MRI with radiation
delivery and the value of adapting our plan during treatment to account for
motion and changes in the tumor and nearby anatomy," said Jun Itami, M.D.,
Ph.D., chair of the Department of Radiation Oncology, NCC. "MRIdian will allow
us to expand the number and types of cancer patients we treat, including some
patients who may have been considered untreatable previously with conventional
radiation therapy."
The National Cancer Center Japan has been providing patient care for more than
50 years. The NCC is at the forefront of research in cancer treatment and plays
a central role in training doctors, nurses and other medical professionals to
specialize in cancer medicine.
"It's exciting to have the first MRIdian treatments in Japan underway at the
NCC," said Chris A. Raanes, president and chief executive officer of ViewRay.
"MRIdian offers significant advantages in its real-time soft-tissue tracking
and on-table adaptive delivery, and we're pleased that patients in Japan are
now experiencing the benefits of this important advance in cancer care."
ViewRay received Shonin approval from the Japanese Ministry of Health, Labor
and Welfare (MHLW) in August 2016 to market the Cobalt-based MRIdian System
within Japan. ViewRay is represented in Japan by ITOCHU Corporation, one of the
three largest general trading companies in Japan. ITOCHU has been focusing on
the healthcare business to promote important medical innovations in Japan for
approximately 40 years.
About ViewRay
ViewRay(R), Inc. (Nasdaq: VRAY), designs, manufactures and markets the
MRIdian(R) radiation therapy system. MRIdian integrates MRI technology,
radiation delivery and proprietary software to locate, target and track the
position and shape of soft-tissue tumors during radiation. ViewRay believes
this combination of enhanced visualization and accuracy will significantly
improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this
press release that are not purely historical are forward-looking statements.
Such forward-looking statements include, among other things, references to the
benefits of the MRIdian System for physicians and patients in Japan and the
first patient treatments by the NCC. Actual results could differ from those
projected in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product development plans,
the inherent uncertainties associated with developing new products or
technologies, competition in the industry in which ViewRay operates and overall
market conditions. These forward-looking statements are made as of the date of
this press release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information set forth
herein and should also refer to the risk factor disclosure set forth in the
reports and other documents ViewRay files with the SEC available at
www.sec.gov.
SOURCE: ViewRay, Inc.
CONTACT: Michael Saracen, Senior Director, Marketing, ViewRay, Inc., Phone:
+1-408-242-2994, Email: media@viewray.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。